Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK HIV vaccine 732462 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | OTHER | Subjects who were administered the GSK HIV vaccine 732462 in primary studies and who accepted to participate in this study |
| Group B | OTHER | Subjects who were administered placebo in primary studies and who accepted to participate in this study |
| Name | Type | Description |
|---|---|---|
| Blood collection | PROCEDURE | Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick. |
| GSK HIV vaccine 732462 | BIOLOGICAL | No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies. |
Inclusion Criteria: All subjects must satisfy ALL the following criteria at study entry: * HIV-infected subject. * Previous participation in a study evaluating GSK HIV vaccine 732462. * Written informed consent obtained from the subject. Exclusion Criteria: The following criteria should be check...
GSK HIV vaccine 732462 is an investigational vaccine candidate developed by GSK plc for AIDS. It is a preventive vaccine modality that has been studied in a Phase 1 clinical trial. The candidate is not approved and remains in clinical development.
GSK HIV vaccine 732462 is being studied for AIDS, the disease caused by HIV infection. The clinical program has focused on evaluating the vaccine in participants with HIV, including long-term follow-up of prior study volunteers. It is not approved for any indication.
GSK HIV vaccine 732462 is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program for this investigational HIV vaccine candidate.
GSK HIV vaccine 732462 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The vaccine is investigational and has not been approved by the FDA or any other regulatory agency.
GSK HIV vaccine 732462 has been evaluated in one completed Phase 1 trial, NCT01092611, titled Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine. The trial enrolled 190 participants across the United States, France, Germany, and Spain, and included controlled, randomized design elements.